Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Price Target Raised to $99.00

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) had its price target lifted by Wedbush from $72.00 to $99.00 in a research note issued to investors on Wednesday,Benzinga reports. The brokerage currently has an outperform rating on the stock.

A number of other research firms have also weighed in on KNSA. Canaccord Genuity Group upped their target price on shares of Kiniksa Pharmaceuticals International from $62.00 to $64.00 and gave the stock a “buy” rating in a report on Wednesday, April 29th. Weiss Ratings lowered Kiniksa Pharmaceuticals International from a “buy (b-)” rating to a “hold (c+)” rating in a report on Tuesday, June 23rd. Wall Street Zen downgraded Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “buy” rating in a research note on Sunday, July 12th. The Goldman Sachs Group raised their target price on Kiniksa Pharmaceuticals International from $60.00 to $75.00 and gave the company a “buy” rating in a report on Thursday, July 23rd. Finally, Zacks Research raised Kiniksa Pharmaceuticals International from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, June 17th. One research analyst has rated the stock with a Strong Buy rating and nine have issued a Buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Buy” and a consensus price target of $87.38.

Kiniksa Pharmaceuticals International Trading Down 4.9%

Shares of KNSA stock opened at $74.34 on Wednesday. The firm has a fifty day simple moving average of $59.04 and a two-hundred day simple moving average of $51.13. Kiniksa Pharmaceuticals International has a 12 month low of $29.90 and a 12 month high of $82.94. The firm has a market capitalization of $5.72 billion, a PE ratio of 76.64 and a beta of 0.07.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last released its quarterly earnings data on Tuesday, July 28th. The company reported $0.30 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.30. The firm had revenue of $243.60 million for the quarter, compared to analyst estimates of $226.49 million. Kiniksa Pharmaceuticals International had a net margin of 9.59% and a return on equity of 13.65%. On average, equities analysts predict that Kiniksa Pharmaceuticals International will post 1.38 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Kiniksa Pharmaceuticals International news, Director G Bradley Cole sold 3,673 shares of Kiniksa Pharmaceuticals International stock in a transaction that occurred on Wednesday, July 29th. The shares were sold at an average price of $81.43, for a total transaction of $299,092.39. Following the transaction, the director owned 11,672 shares of the company’s stock, valued at $950,450.96. This trade represents a 23.94% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 51.98% of the company’s stock.

Hedge Funds Weigh In On Kiniksa Pharmaceuticals International

A number of hedge funds and other institutional investors have recently made changes to their positions in KNSA. Mark Sheptoff Financial Planning LLC boosted its holdings in shares of Kiniksa Pharmaceuticals International by 1.6% in the fourth quarter. Mark Sheptoff Financial Planning LLC now owns 16,350 shares of the company’s stock worth $674,000 after acquiring an additional 250 shares during the period. Mariner LLC boosted its stake in Kiniksa Pharmaceuticals International by 2.0% in the 4th quarter. Mariner LLC now owns 13,519 shares of the company’s stock worth $558,000 after purchasing an additional 266 shares during the period. First Trust Advisors LP boosted its stake in Kiniksa Pharmaceuticals International by 3.1% in the 1st quarter. First Trust Advisors LP now owns 9,876 shares of the company’s stock worth $476,000 after purchasing an additional 293 shares during the period. Virtus Investment Advisers LLC grew its holdings in Kiniksa Pharmaceuticals International by 2.5% during the 4th quarter. Virtus Investment Advisers LLC now owns 16,432 shares of the company’s stock valued at $678,000 after buying an additional 406 shares in the last quarter. Finally, Mercer Global Advisors Inc. ADV grew its holdings in Kiniksa Pharmaceuticals International by 7.1% during the 4th quarter. Mercer Global Advisors Inc. ADV now owns 7,684 shares of the company’s stock valued at $317,000 after buying an additional 508 shares in the last quarter. 53.95% of the stock is owned by hedge funds and other institutional investors.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.